Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 29;14(3):887.
doi: 10.3390/jcm14030887.

Nanotechnology and Artificial Intelligence in Dyslipidemia Management-Cardiovascular Disease: Advances, Challenges, and Future Perspectives

Ewelina Młynarska  1 , Kinga Bojdo  1 , Hanna Frankenstein  1 , Natalia Kustosik  1 , Weronika Mstowska  1 , Aleksandra Przybylak  1 , Jacek Rysz  2 , Beata Franczyk  1
Affiliations
Review

Nanotechnology and Artificial Intelligence in Dyslipidemia Management-Cardiovascular Disease: Advances, Challenges, and Future Perspectives

Ewelina Młynarska et al. J Clin Med. .

Abstract

This narrative review explores emerging technologies in dyslipidemia management, focusing on nanotechnology and artificial intelligence (AI). It examines the current treatment recommendations and contrasts them with the future prospects enabled by these innovations. Nanotechnology shows significant potential in enhancing drug delivery systems, enabling more targeted and efficient lipid-lowering therapies. In parallel, AI offers advancements in diagnostics, cardiovascular risk prediction, and personalized treatment strategies. AI-based decision support systems and machine learning algorithms are particularly promising for analyzing large datasets and delivering evidence-based recommendations. Together, these technologies hold the potential to revolutionize dyslipidemia management, improving outcomes and optimizing patient care. In addition, this review covers key topics such as cardiovascular disease biomarkers and risk factors, providing insights into the current methods for assessing cardiovascular risk. It also discusses the current understanding of dyslipidemia, including pathophysiology and clinical management. Together, these insights and technologies hold the potential to revolutionize dyslipidemia management, improving outcomes and optimizing patient care.

Keywords: artificial intelligence; cardiovascular disease; cardiovascular risk-related biomarkers; dyslipidemia; emerging lipid-lowering therapies; nanotechnology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Comparison of orally delivered statins and statins delivered via NPs; NPs—nanoparticles [59].
Figure 2
Figure 2
Maximum drug release across nanoparticle types and pure drug; PLGA NPs—poly lactide-co-glycolic acid nanoparticles; PLGA-DSPE-PEG NPs—polymer–lipid hybrid nanoparticles for loading atorvastatin [73].
Figure 3
Figure 3
Efficacy of drug-loaded nanoparticles vs. pure drug; PLGA NPs—poly lactide-co-glycolic acid nanoparticles; PLGA-DSPE-PEG NPs—polymer–lipid hybrid nanoparticles for loading atorvastatin; TC—total cholesterol; LDL—low-density lipoprotein; TG—triglyceride; HDL—high-density lipoprotein [73].
See this image and copyright information in PMC

References

    1. Global Cardiovascular Risk Consortium. Magnussen C., Ojeda F.M., Leong D.P., Alegre-Diaz J., Amouyel P., Aviles-Santa L., De Bacquer D., Ballantyne C.M., Bernabé-Ortiz A., et al. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N. Engl. J. Med. 2023;389:1273–1285. doi: 10.1056/NEJMoa2206916. - DOI - PMC - PubMed
    1. Shaya G.E., Leucker T.M., Jones S.R., Martin S.S., Toth P.P. Coronary heart disease risk: Low-density lipoprotein and beyond. Trends Cardiovasc. Med. 2022;32:181–194. doi: 10.1016/j.tcm.2021.04.002. - DOI - PubMed
    1. Katta N., Loethen T., Lavie C.J., Alpert M.A. Obesity and Coronary Heart Disease: Epidemiology, Pathology, and Coronary Artery Imaging. Curr. Probl. Cardiol. 2021;46:100655. doi: 10.1016/j.cpcardiol.2020.100655. - DOI - PubMed
    1. Medina-Leyte D.J., Zepeda-García O., Domínguez-Pérez M., González-Garrido A., Villarreal-Molina T., Jacobo-Albavera L. Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. Int. J. Mol. Sci. 2021;22:3850. doi: 10.3390/ijms22083850. - DOI - PMC - PubMed
    1. Francula-Zaninovic S., Nola I.A. Management of Measurable Variable Cardiovascular Disease’ Risk Factors. Curr. Cardiol. Rev. 2018;14:153–163. doi: 10.2174/1573403X14666180222102312. - DOI - PMC - PubMed

LinkOut - more resources